Abstract
Survivors of severe SARS-CoV-2 infections frequently suffer from a range of post-infection sequelae. Whether survivors of mild or asymptomatic infections can expect any long-term health consequences is not yet known. Herein we investigated lasting changes to soluble inflammatory factors and cellular immune phenotype and function in individuals who had recovered from mild SARS-CoV-2 infections (n=22) compared to those that had recovered from other mild respiratory infections (n=11). Individuals who had mild SARS-CoV-2 infections had elevated levels of C-reactive protein 1-3 months after symptom onset, and changes in phenotype and function of circulating T cells that were not apparent in individuals 6-9 months post-symptom onset. Markers of monocyte activation and expression of adherence and chemokine receptors indicative of altered migratory capacity were also higher at 1-3 months post-infection in individuals who had mild SARS-CoV-2, but these were no longer elevated by 6-9 months post-infection. Perhaps most surprisingly, polyclonal activation of T cells was higher in individuals who had recently experienced a mild SARS-CoV-2 infection compared to individuals with other recent respiratory infections. These data are indicative of prolonged immune activation and systemic inflammation that persists for up to three months after mild or asymptomatic SARS-CoV-2 infections.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a grant from the W. Garfield Weston Family Foundation to DMEB, the Canadian Institutes of Health Research FDN-154304 to MKL and Ontario Research Fund (ORF) COVID-19 Rapid Research Fund (#C-191-2426729-NAZY) to IN. DMEB is the Canada Research Chair in Aging & Immunity. AEK was supported by a Thode Fellowship. JAB is supported by a McMaster Institute for Research on Aging Postdoctoral Fellowship. HS is supported by the CSV United Supermarket Studentship in SARS-Cov-2 Research and an Ontario Graduate Scholarship. MM is supported by Canadian Institutes of Health Research/Canadian Allergy Asthma Immunology Foundation/ Emerging Researcher Award. PN is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. MKL is supported by a BCCHR salary award and is the Canada Research Chair in Engineered Immune Tolerance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All protocols were approved by the Hamilton Research Ethics Board (#10757 and #11471).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵¶ AEK and LC are Joint Senior Authors
Data Availability
Data from this study are available from the corresponding author upon reasonable request.
